Vertex offers ‘portfolio approach’ to secure access to CF meds

Vertex has presented NHS England with an “innovative long-term framework proposal” that hopes to secure access for all eligible patients to its current and future portfolio of cystic fibrosis (CF) medicines.

Read on PharmaTimes

NICE gives three nods in thyroid cancer

Ipsen’s Cometriq and Bayer’s Nexavar to come off the Cancer Drugs Fund and into routine NHS use

Read on PharmaTimes

Janssen’s psoriasis biologic Tremfya shows long-term effect

Top-line trial data unveiled by Janssen at the 2018 American Academy of Dermatology (AAD) Annual Meeting over the weekend indicate that the benefit of Tremfya in patients with severe plaque psoriasis is maintained in the long-term.

Read on PharmaTimes

Manchester CRN gets ‘Premier Site’ status from Sanofi

French drugmaker Sanofi has named NIHR Clinical Research Network Greater Manchester as its first UK Premier Site, marking a “landmark” clinical research partnership that will help accelerate R&D to address the medical need of patients.

Read on PharmaTimes

US clears AZ’ Imfinzi for lung cancer

US regulators have expanded the scope of AstraZeneca/MedImmune’s immunotherapy Imfinzi to include patients with a certain form of lung cancer.

Read on PharmaTimes

1 2 3

Top of page

Industry News

Vertex has presented NHS England with an “innovative long-term framework proposal” that hopes to secure access for all eligible patients...
Read More >

More Stories

News

Recent launch of several new categories of compound which include the spirocyclic β-Lactams designed...
Read More >

More Stories

Latest Tweets

Follow Us